# University of Chicago **Type:** Institutions **Canonical URL:** https://scholariq.org/institutions/university-of-chicago/ ## Facts | Field | Value | | --- | --- | | Avg h-index | 68.3 | | Citations | 35,186,387 | | City | Chicago | | Country | US | | Description | University of Chicago is a research organisation in Chicago, US. OpenAlex records 312,779 works and 35,186,387 citations for it. 45,513 researchers list it as their most recent affiliation. | | Homepage | https://www.uchicago.edu | | OpenAlex ID | https://openalex.org/I40347166 | | Region | Illinois | | Researchers | 45,513 | | ROR ID | https://ror.org/024mw5h28 | | Type | education | | Wikidata ID | Q131252 | | Works | 312,779 | ## University collaborators - [Johns Hopkins University](https://scholariq.org/institutions/johns-hopkins-university/) - [The Ohio State University](https://scholariq.org/institutions/the-ohio-state-university/) - [Harvard University](https://scholariq.org/institutions/harvard-university/) - [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/) - [Merck & Co., Inc., Rahway, NJ, USA (United States)](https://scholariq.org/institutions/merck-and-co-inc-rahway-nj-usa-united-states/) - [University of Pennsylvania](https://scholariq.org/institutions/university-of-pennsylvania/) - [Dana-Farber Cancer Institute](https://scholariq.org/institutions/dana-farber-cancer-institute/) - [University of Michigan](https://scholariq.org/institutions/university-of-michigan/) ## University papers Showing 12 of 268. - [Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer/) - [Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer/) - [Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-metastatic-non-small-cell-lung-cancer/) - [Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck](https://scholariq.org/papers/nivolumab-for-recurrent-squamous-cell-carcinoma-of-the-head-and-neck/) - [Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/anaplastic-lymphoma-kinase-inhibition-in-non-small-cell-lung-cancer/) - [Long-Term Use of a Left Ventricular Assist Device for End-Stage Heart Failure](https://scholariq.org/papers/long-term-use-of-a-left-ventricular-assist-device-for-end-stage-heart-failure/) - [Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU](https://scholariq.org/papers/clinical-practice-guidelines-for-the-prevention-and-management-of-pain-agitation/) - [Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial](https://scholariq.org/papers/atezolizumab-in-patients-with-locally-advanced-and-metastatic-urothelial/) - [2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults](https://scholariq.org/papers/2009-focused-update-incorporated-into-the-acc-aha-2005-guidelines-for-the/) - [Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer](https://scholariq.org/papers/osimertinib-or-platinum-pemetrexed-in-i-egfr-i-t790m-positive-lung-cancer/) - [Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial](https://scholariq.org/papers/early-physical-and-occupational-therapy-in-mechanically-ventilated-critically/) - [Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses](https://scholariq.org/papers/recommendations-for-conduct-methodological-practices-and-reporting-of-cost/) ## University researchers - [Marina Chiara Garassino](https://scholariq.org/researchers/marina-chiara-garassino/) - [Yan Li](https://scholariq.org/researchers/yan-li-3/) - [Arlene B. Chapman](https://scholariq.org/researchers/arlene-b-chapman/) - [Sooyoung Lee](https://scholariq.org/researchers/sooyoung-lee/) - [Nan Chen](https://scholariq.org/researchers/nan-chen-2/) - [Jingxin Wang](https://scholariq.org/researchers/jingxin-wang/) - [Rami Z. Morsi](https://scholariq.org/researchers/rami-z-morsi/) - [Jessica Dai](https://scholariq.org/researchers/jessica-dai/) - [Elizabeth Wall](https://scholariq.org/researchers/elizabeth-wall/) - [Joseph Tasosa](https://scholariq.org/researchers/joseph-tasosa/) - [Edward Lozano](https://scholariq.org/researchers/edward-lozano/) - [EverettE Vokes](https://scholariq.org/researchers/everette-vokes/) - [Hedy Kindler](https://scholariq.org/researchers/hedy-kindler/) ## University top topics Showing 8 of 23. - [Particle physics theoretical and experimental studies](https://scholariq.org/topics/particle-physics-theoretical-and-experimental-studies/) - [Galaxies: Formation, Evolution, Phenomena](https://scholariq.org/topics/galaxies-formation-evolution-phenomena/) - [Cosmology and Gravitation Theories](https://scholariq.org/topics/cosmology-and-gravitation-theories/) - [Stellar, planetary, and galactic studies](https://scholariq.org/topics/stellar-planetary-and-galactic-studies/) - [Dark Matter and Cosmic Phenomena](https://scholariq.org/topics/dark-matter-and-cosmic-phenomena/) - [Quantum Chromodynamics and Particle Interactions](https://scholariq.org/topics/quantum-chromodynamics-and-particle-interactions/) - [High-Energy Particle Collisions Research](https://scholariq.org/topics/high-energy-particle-collisions-research/) - [Astro and Planetary Science](https://scholariq.org/topics/astro-and-planetary-science/) --- Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.